I expected Bristol-Myers Squibb Company stock to keep rising in value through 2023 and perhaps reach triple figures. Instead, the share price has fallen 5% this year as inflationary headwinds and drug

10 Dividend Growth Stocks - March 2023

09:00am, Sunday, 26'th Mar 2023
This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. To rank stocks, I sort them in descending order by quality s
Despite dealing with a pharmaceutical company, Bristol-Myers Squibb's performance during recessions was mixed and the stock also performed horrible in the last two decades. For fiscal 2022, the compan
Investors have assigned a higher multiple to LLY stock due to its robust pipeline and better profitability, as discussed below If we look at stock returns, Eli Lilly, with 15% returns in the last twel
Look no further if you want yield and distribution growth in a large-cap name with a blue-chip appeal. A simple screen using Marketbeat.com's dividend screener will turn up names like Comcast (NASDAQ
Bristol Myers Squibb is counting on new approvals to fill the hole left by older medicines. Novo Nordisk is second to none in diabetes care, and it is expanding beyond this area.
Bristol Myers and Verizon both pay above-average dividend yields. These payouts are not only safe but could potentially grow as well.
Investors are often on the lookout for strong companies that may be undervalued and present lucrative long-term opportunities.
Start Time: 09:50 January 1, 0000 10:22 AM ET Bristol-Myers Squibb Company (NYSE:BMY ) Cowen 43rd Annual Healthcare Conference March 07, 2023, 09:50 AM ET Company Participants Samit Hirawat - EVP, Chi
Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult pa
Bristol Myers Squibb stock (NYSE: BMY) has seen a fall of 3% in a month, compared with -4% returns for the broader S&P500 index.

Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales

02:22pm, Wednesday, 01'st Mar 2023 Zacks Investment Research
Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.
The simple black dress is considered a foundational piece. It just doesn't go out of fashion.

This Big Pharma Stock Is a Clear Buy

12:40pm, Sunday, 26'th Feb 2023 The Motley Fool
This drugmaker is one of the most well-known in the world.

This Big Pharma Stock Is a Clear Buy

07:40am, Sunday, 26'th Feb 2023
This drugmaker is one of the most well-known in the world.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE